F Consoli1, M Bersanelli2, G Perego3, S Grisanti1, B Merelli4, A Berruti1, F Petrelli5. 1. Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Medical Oncology, University of Brescia at ASST-Spedali Civili, Brescia, Italy. 2. Oncology Unit, University Hospital of Parma, Parma, Italy. 3. Università Degli Studi Di Milano, Facoltà Di Farmacia, Pharmacy Unit, ASST Bergamo Ovest, Treviglio, BG, Italy. 4. Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy. 5. Oncology Unit, ASST Bergamo Ovest, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy. faupe@libero.it.
Abstract
BACKGROUD: Synergistic combinations between BRAF and MEK inhibitors, such as dabrafenib plus trametinib, vemurafenib plus cobimetinib or encorafenib plus binimetinib, represent the current standard of care in metastatic or locally advanced BRAF V600 mutated malignant melanomas (MM). However, no studies explored the direct head-to-head comparison between the three different combinations. In this paper, we performed a network meta-analysis to evaluate their efficacy in terms of overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and safety profile. METHOD: We performed a systematic review of the literature about published first line trials of BRAF and MEK inhibitors doublets in advanced mutated malignant melanoma. We compared then the results with an adjusted indirect analysis of randomized-controlled trials. Our primary survival outcome was OS. Secondary endpoints were PFS, ORR, G3-4 toxicities described in at least 5% of patients in experimental arms. RESULTS: We identified three phase-3 trials: coBRIM (vemurafenib and cobimetinib), COMBI-v (dabrafenib and trametinib) and Columbus study (encorafenib and binimetinib) for a total of 1230 included patients. The control arm was vemurafenib in all studies. The indirect comparison revealed no statistically differences for OS, PFS and ORR across trials, while safety profile differed between the three couples of agents. CONCLUSION: This indirect adjusted meta-analysis suggests a similar efficacy and a slightly different safety profile, related to specific molecular properties of the three different BRAF and MEK inhibitors currently approved in the management of advanced MM.
BACKGROUD: Synergistic combinations between BRAF and MEK inhibitors, such as dabrafenib plus trametinib, vemurafenib plus cobimetinib or encorafenib plus binimetinib, represent the current standard of care in metastatic or locally advanced BRAF V600 mutated malignant melanomas (MM). However, no studies explored the direct head-to-head comparison between the three different combinations. In this paper, we performed a network meta-analysis to evaluate their efficacy in terms of overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and safety profile. METHOD: We performed a systematic review of the literature about published first line trials of BRAF and MEK inhibitors doublets in advanced mutated malignant melanoma. We compared then the results with an adjusted indirect analysis of randomized-controlled trials. Our primary survival outcome was OS. Secondary endpoints were PFS, ORR, G3-4 toxicities described in at least 5% of patients in experimental arms. RESULTS: We identified three phase-3 trials: coBRIM (vemurafenib and cobimetinib), COMBI-v (dabrafenib and trametinib) and Columbus study (encorafenib and binimetinib) for a total of 1230 included patients. The control arm was vemurafenib in all studies. The indirect comparison revealed no statistically differences for OS, PFS and ORR across trials, while safety profile differed between the three couples of agents. CONCLUSION: This indirect adjusted meta-analysis suggests a similar efficacy and a slightly different safety profile, related to specific molecular properties of the three different BRAF and MEK inhibitors currently approved in the management of advanced MM.
Authors: Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean Jacques Grob; Vanna Chiarion Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymyr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Michelle Casey; Daniele Ouellet; Anne-Marie Martin; Ngocdiep Le; Kiran Patel; Keith Flaherty Journal: N Engl J Med Date: 2014-09-29 Impact factor: 91.245
Authors: Selma Ugurel; Joachim Röhmel; Paolo A Ascierto; Keith T Flaherty; Jean Jacques Grob; Axel Hauschild; James Larkin; Georgina V Long; Paul Lorigan; Grant A McArthur; Antoni Ribas; Caroline Robert; Dirk Schadendorf; Claus Garbe Journal: Eur J Cancer Date: 2017-08-23 Impact factor: 9.162
Authors: Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman Journal: Lancet Date: 2012-06-25 Impact factor: 79.321
Authors: Grant A McArthur; Paul B Chapman; Caroline Robert; James Larkin; John B Haanen; Reinhard Dummer; Antoni Ribas; David Hogg; Omid Hamid; Paolo A Ascierto; Claus Garbe; Alessandro Testori; Michele Maio; Paul Lorigan; Celeste Lebbé; Thomas Jouary; Dirk Schadendorf; Stephen J O'Day; John M Kirkwood; Alexander M Eggermont; Brigitte Dréno; Jeffrey A Sosman; Keith T Flaherty; Ming Yin; Ivor Caro; Suzanne Cheng; Kerstin Trunzer; Axel Hauschild Journal: Lancet Oncol Date: 2014-02-07 Impact factor: 41.316
Authors: James Larkin; Michele Del Vecchio; Paolo A Ascierto; Ivana Krajsova; Jacob Schachter; Bart Neyns; Enrique Espinosa; Claus Garbe; Vanna Chiarion Sileni; Helen Gogas; Wilson H Miller; Mario Mandalà; Geke A P Hospers; Ana Arance; Paola Queirolo; Axel Hauschild; Michael P Brown; Lada Mitchell; Luisa Veronese; Christian U Blank Journal: Lancet Oncol Date: 2014-02-27 Impact factor: 41.316
Authors: Fei Su; Amaya Viros; Carla Milagre; Kerstin Trunzer; Gideon Bollag; Olivia Spleiss; Jorge S Reis-Filho; Xiangju Kong; Richard C Koya; Keith T Flaherty; Paul B Chapman; Min Jung Kim; Robert Hayward; Matthew Martin; Hong Yang; Qiongqing Wang; Holly Hilton; Julie S Hang; Johannes Noe; Maryou Lambros; Felipe Geyer; Nathalie Dhomen; Ion Niculescu-Duvaz; Alfonso Zambon; Dan Niculescu-Duvaz; Natasha Preece; Lídia Robert; Nicholas J Otte; Stephen Mok; Damien Kee; Yan Ma; Chao Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Hoa Nguyen; Mark Kockx; Luc Andries; Brian Lestini; Keith B Nolop; Richard J Lee; Andrew K Joe; James L Troy; Rene Gonzalez; Thomas E Hutson; Igor Puzanov; Bartosz Chmielowski; Caroline J Springer; Grant A McArthur; Jeffrey A Sosman; Roger S Lo; Antoni Ribas; Richard Marais Journal: N Engl J Med Date: 2012-01-19 Impact factor: 91.245
Authors: Liang Cheng; Antonio Lopez-Beltran; Francesco Massari; Gregory T MacLennan; Rodolfo Montironi Journal: Mod Pathol Date: 2017-11-17 Impact factor: 7.842
Authors: Alexander Schulz; Jennifer Raetz; Paula C Karitzky; Lisa Dinter; Julia K Tietze; Isabell Kolbe; Theresa Käubler; Bertold Renner; Stefan Beissert; Friedegund Meier; Dana Westphal Journal: Cancers (Basel) Date: 2022-10-08 Impact factor: 6.575